Although real-time continuous glucose monitoring (rtCGM), which measures the interstitial fluid glucose concentration continuously without much difficulty, facilitates the adjustment of insulin dosage (Rodbard, 2017), its adoption in the T2DM population is strictly limited by insurance coverage and lack of awareness of rtCGM among clinicians. This evidence concerns the gene INS and type 2 diabetes mellitus.